| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.077 | 0.1 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.1 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.045 | 0.1 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.05 | 0.1 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.2 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.2 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | -0.053 | 0.2 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |